Nanjing Leads Biolabs Co., Ltd. (HKG:9887)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
65.80
+4.85 (7.96%)
Mar 10, 2026, 4:08 PM HKT
Market Cap 12.12B
Revenue (ttm) n/a
Net Income (ttm) -314.72M
Shares Out 198.89M
EPS (ttm) -2.04
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 2,570,409
Average Volume 616,693
Open 59.80
Previous Close 60.95
Day's Range 59.80 - 66.95
52-Week Range 44.72 - 83.60
Beta n/a
RSI 57.54
Earnings Date May 29, 2026

About Nanjing Leads Biolabs

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinica... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 192
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9887
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements

News

There is no news available yet.